Sionna Therapeutics has raised $182 million in financing to advance the development of small molecules designed to restore CFTR…
Articles by Marisa Wexler, MS
A lipid nanoparticle designed to deliver genetic therapy to lung cells could be used as a platform to treat lung-related…
A persistently stuffy nose is a big concern for people with cystic fibrosis (CF) who have chronic nose inflammation,…
In the years after Kalydeco (ivakaftor) became available, the use of pancreatic enzyme replacement therapy (PERT) fell among…
Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly reduced rates of colonization with the bacterium Pseudomonas aeruginosa in adults with cystic…
Compounds secreted by Lactobacillus, a group of bacteria commonly used in probiotics, are able to impede the growth of Pseudomonas…
Intellia Therapeutics and ReCode Therapeutics are joining forces to develop new genomic medicines for people with cystic…
The frequent use of aminoglycosides — a class of antibiotics commonly used to help treat lung infections in people with…
A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor —…
Enterprise Therapeutics has raised £26 million (nearly $33 million USD) in series B financing, which the company is planning…